The Pennsylvania Supreme Court denied defendants' petition for allowance of appeal in Syngenta Crop Protection v. Nemeth, leaving unresolved the lingering uncertainty that has followed the U.S.

The hope is that these investments lead to products like Johnson & Johnson’s Spravato, a form of ketamine used in treatment-resistant depression as well as certain cases of major depression. Sales ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the immediate impact Spravato has had on patients with treatment-resistant ...

An estimated 21 million American adults suffer from clinical depression. © 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

The UK healthcare cost-effectiveness agency has said it will not recommend funding for Johnson & Johnson’s antidepressant nasal spray Spravato on the NHS, because of cost and clinical concerns.

Wells Fargo WFC1.43%increase; green up pointing triangle said Tuesday that its 2022 consent order with the Consumer Financial Protection Bureau relating to auto lending, consumer deposit accounts ...

Mr Arora was charged with three counts of intentionally record intimate image without consent and three counts of behave in offensive manner in/near public place/school. Police escort Kamal Arora ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the approval of Spravato for treatment-resistant depression. PE: How does ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...

Drug is the first and only approved monotherapy for refractory major depressive disorder. (HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

Parkside Psychiatric Hospital in Tulsa has an on-site Spravato outpatient clinic that sees over 20 patients per week. According to Parkside, these patients are seen at least twice a week for the ...